AREG knockdown, neutralizing the antibodies of AREG, and co-treatment with NSCLC-exosomes and epidermal growth factor receptor–tyrosine kinase inhibitor Erlotinib revert the osteoclast differentiation induced by exosomes [68]. Here, AREG is linked to non-small cell lung carcinoma.